Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
|ClinicalTrials.gov Identifier: NCT00014729|
Recruitment Status : Completed
First Posted : April 11, 2001
Last Update Posted : March 25, 2015
I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis bullosa.
|Condition or disease||Intervention/treatment||Phase|
|Epidermolysis Bullosa||Drug: isotretinoin||Phase 1|
Patients receive oral isotretinoin daily for 8 months in the absence of disease progression or unacceptable toxicity.
Completion date provided represents the completion date of the grant per OOPD records
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Study Start Date :||October 2000|
|Study Completion Date :||September 2002|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00014729
|Study Chair:||Jo-David Fine||University of North Carolina|